Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. (NYSE: AVTR) is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. This news page aggregates company announcements, earnings updates and other disclosures so readers can follow how Avantor’s operations, portfolio and governance evolve over time.
Recent news releases describe Avantor’s participation in investor conferences, quarterly earnings reports, leadership and board appointments, and product and service developments. Examples include announcements about the timing of quarterly and full-year earnings releases and related conference calls, as well as participation in events such as the J.P. Morgan Healthcare Conference. These items provide context on how the company communicates with the investment community and presents its financial performance.
Product- and operations-focused news highlights areas such as bioprocessing, biomanufacturing and laboratory services. Avantor has reported the launch of a sterile sampling platform and PUPSIT assemblies for bioprocessing, the development of a biodegradable viral inactivation detergent recognized with an Edison Patent Award, and the expansion of its Centralized Service Center model with a facility serving the Greater Boston area. These updates illustrate how the company positions its tools and services within scientific and industrial workflows.
Corporate governance news includes the appointment of new directors and senior executives, such as additions to the Board of Directors and the creation of an Executive Vice President and Chief Operating Officer role. Together, these news items offer insight into Avantor’s strategic priorities, leadership changes and ongoing initiatives. Investors, analysts and industry participants can use this page to monitor company communications and official announcements over time.
Invesco Mortgage Capital (NYSE: IVR) declared a cash dividend of $0.12 per common share for January 2026, payable February 13, 2026, to holders of record on January 26, 2026 (ex-dividend January 26, 2026).
As of January 12, 2026 management estimates book value per common share at $8.94 to $9.30, a debt-to-equity ratio of 6.5x, and an economic debt-to-equity ratio of 6.9x. Repurchase agreements total $5.6 billion and TBAs at implied cost are $385.4 million. These figures are preliminary, unaudited estimates and may change.
Avantor (NYSE: AVTR) will release its fourth quarter and full year 2025 financial results before market open on Wednesday, February 11, 2026. The company will host a conference call the same day at 8:00 a.m. Eastern Standard Time to discuss the results. Investors can listen via a live audio webcast on the Investor Events & Presentations page at ir.avantorsciences.com. A replay of the webcast will be available for 30 days following the live session.
Avantor (NYSE: AVTR) announced that Emmanuel Ligner, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at approximately 8:15 a.m. Pacific Standard Time. A live audio webcast will be available through the company’s Investor Events & Presentations page at ir.avantorsciences.com, and a replay will be accessible for 30 days.
Avantor (NYSE: AVTR) announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Dingemans brings global leadership experience across healthcare, finance and strategic transformation, having served as CFO of GlaxoSmithKline, a partner at Goldman Sachs, and a managing director at The Carlyle Group.
The company said the appointment supports the Avantor Revival plan, aiming to accelerate growth, profitability and operational improvement, and noted Dingemans currently serves on the boards of Vodafone and WPP.
Avantor (NYSE: AVTR) appointed Sanjeev Mehra to its Board of Directors, effective December 4, 2025. Mr. Mehra is co-founder and managing partner of Periphas Capital and previously spent over 30 years at Goldman Sachs, including roles as Vice Chairman of Global Private Equity and co-head of US Private Equity.
The company said Mehra will support execution of the Avantor Revival plan with a focus on accelerating growth and increasing profitability, and he joins other public‑company boards including OPENLANE and ShipMonk.
Avantor (NYSE: AVTR) and Amgen received a 2025 Edison Patent Award from the Research & Development Council of New Jersey for a biodegradable detergent that enables safer, more sustainable viral inactivation in biomanufacturing.
The jointly developed detergent is described as delivering effective viral inactivation while maintaining protein integrity and increasing process yield, providing an environmentally responsible alternative for producing monoclonal antibodies, vaccines, and gene therapies. Work was co-developed at Avantor's Bridgewater Innovation Center and highlights industry collaboration and New Jersey's role in scientific innovation.
Avantor (NYSE: AVTR) announced on November 19, 2025 the opening of a new Centralized Service Center in Watertown, Massachusetts to serve the Greater Boston area. The facility provides off-site support for non-core lab services including glassware washing, autoclaving, media and buffer preparation, chemical management, and logistics to help organizations reclaim lab space, reduce operational complexity, and accelerate research.
The Watertown CSC integrates digital tools, SmartShelves asset tracking, daily logistics, and scalable services for pharmaceutical, biotech, academic, medtech, and advanced materials R&D customers.
Avantor (NYSE: AVTR) appointed Mary Blenn as Executive Vice President and Chief Operating Officer, effective Nov 10, 2025.
Ms. Blenn will report to President and CEO Emmanuel Ligner and lead the company's manufacturing and supply chain operations, with responsibility for aligning the manufacturing and logistics network to growth strategy, improving efficiency and scalability, and maintaining quality and reliability for customers. She brings over three decades of global operations, manufacturing, and supply chain leadership, including senior roles at Cytiva and General Electric, with experience in M&A integration, risk management, and compliance.
Avantor (NYSE: AVTR) on October 30, 2025 launched a next-generation sterile sampling platform and pre-engineered PUPSIT assemblies to streamline bioprocessing qualification and in-process decision-making.
The suite includes NBSS (needle-based), NFSS (needle-free), EVSS (exact-volume sampling) and OmniTop, offering modular multi-sample configurations, closed-path designs, standardized bills of materials, and supplier-agnostic PUPSIT assemblies that integrate with common filtration trains to reduce line breaks, operator intervention, and setup variability.
Avantor says the products support single-use and hybrid facilities across clinical to commercial scale, aiming to improve product protection, operational safety, and speed of decisions.
Avantor (NYSE: AVTR) reported Q3 2025 results for the quarter ended September 30, 2025: net sales $1.62B (down 5.3% YoY), net loss $712M and GAAP diluted loss per share of $1.04, driven by a $785M non-cash goodwill impairment in the Distribution reporting unit.
Adjusted results included Adjusted EBITDA $267.9M, adjusted EPS $0.22, operating cash flow $207.4M, free cash flow $171.7M, and adjusted net leverage of 3.1x. The Board authorized a $500M share repurchase program. A conference call and webcast were scheduled for October 29, 2025 at 8:00 AM ET.
FAQ
What is the current stock price of Avantor (AVTR)?
What is the market cap of Avantor (AVTR)?
